C-reactive protein and B-type natriuretic peptides in never-treated white coat hypertensives

David Conen1, Thomas Dieterle, Katrin Utech

  • 1Medical Outpatient Clinic, University Hospital Basel, Basel, Switzerland. conend@uhbs.ch

Insights

Patients with white coat hypertension and sustained hypertension show similar C-reactive protein (CRP) and B-type natriuretic peptide (BNP) levels. However, both hypertensive groups had higher CRP than controls, indicating inflammation in hypertension.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Biomarker Analysis

Background:

  • Arterial hypertension is linked to elevated C-reactive protein (CRP) and B-type natriuretic peptide (BNP) plasma concentrations.
  • Inflammatory markers and cardiac strain indicators may differ between various hypertension subtypes.

Purpose of the Study:

  • To investigate if white coat hypertension (WCH) is associated with lower CRP and BNP levels compared to sustained hypertension (SH).
  • To compare inflammatory and cardiac biomarkers in patients with WCH, SH, and normotensive controls.

Main Methods:

  • Ambulatory blood pressure monitoring and blood sampling for CRP and BNP were performed in 109 never-treated hypertensive outpatients.
  • Exclusion criteria included treated hypertension, lipid-lowering therapy, renal insufficiency, and structural heart disease.
  • WCH defined as office hypertension with mean daytime BP < 135/85 mmHg; controls (n=48) were normotensive.

Main Results:

  • No significant difference in mean CRP (3.2±5.1 vs. 3.4±4.2 mg/l, p=0.79) or BNP (21±25 vs. 44±125 pg/l, p=0.36) between WCH and SH groups.
  • Both WCH and SH groups exhibited significantly higher CRP levels than normotensive controls (p=0.002 and p=0.038, respectively).
  • Baseline variables were similar between WCH and SH, except for blood pressure values.

Conclusions:

  • Plasma CRP and BNP concentrations do not differ between patients with white coat hypertension and sustained hypertension.
  • Both WCH and SH are associated with elevated CRP compared to normotensive individuals, suggesting a common inflammatory component.
  • These findings challenge the hypothesis that WCH represents a milder form of hypertension regarding these specific biomarkers.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Antihypertensive Drugs: Action of &#946;1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: